Cancer

Title
The Study of Adding the Drug Trastuzumab to the Standard Chemotherapy and Radiation Therapy Plan for Individuals with Esophageal Cancer
Trial Number
203315031611
Number of Participants
480
Principal Investigator
Eligibility

Patients must be 18 years of age or older and have pathologically confirmed primary adenocarcinoma of the esophagus that involves the mid (up to 25 cm), distal or esophagogastric junction. The cancer may involve the stomach up to 5 cm. Patients must have an endoscopy and a biopsy with the intent to submit tissue for central HER2 testing. The cancer must be stage T1N1-2, T2-3 N0-N2. Patients must have a chest/abdominal/pelvic CT or a whole body PET/CT.

Purpose

The purpose of this study is to determine whether the addition of the drug trastuzumab to the standard treatment regimen for esophageal cancer can help prevent your cancer from growing back.

Enrollment

(708) 216-2568

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.